{
    "clinical_study": {
        "@rank": "166701", 
        "acronym": "PREVENT", 
        "arm_group": {
            "arm_group_label": "PREVENT study patients", 
            "description": "Patients with locally advanced prostate cancer with high and very high risk of recurrence, who underwent surgery or radiotherapy within 3 months prior to enrolment, 18 years and older, consented to participate in this non-interventional study, being treated for prostate cancer in the oncology institutions / departments in the Russian Federation."
        }, 
        "brief_summary": {
            "textblock": "This is a multicentre, non-interventional, prospective study to be carried out in\n      representative medical institutions in order to get the information on administration of\n      postoperative and post-radiation adjuvant androgen deprivation therapy (including \"go\" / \"no\n      go\" decision, regimens, dosages and duration) used in locally advanced prostate cancer\n      patients with high and very high risk of recurrence  in Russia."
        }, 
        "brief_title": "Non-Interventional Study PREVENT", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Postoperative or Postradiation Ajuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a multicentre, non-interventional, prospective study to be carried out in\n      representative medical institutions in order to get the information on administration of\n      postoperative and post-radiation adjuvant androgen deprivation therapy (including \"go\" / \"no\n      go\" decision, regimens, dosages and duration) used in locally advanced prostate cancer\n      patients with high and very high risk of recurrence  in Russia.\n\n      No additional procedures besides those already used in the routine clinical practice will be\n      applied to the patients. Treatment assignment will be done according to the current\n      practice.\n\n      It is planned to enrol 200 subjects in up to 30 sites in Russian Federation. The average\n      number of patients per site is planned as 6 - 10; there are no restrictions on minimum and\n      maximum number of subjects per site in this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The voluntarily given informed consent, confirmed by the Informed Consent Form,\n             properly signed by both the subject and the investigator.\n\n          2. Locally advanced stage of PCa  (stage T3-T4, Nx-N0, M0: prostate adenocarcinoma with\n             extracapsular invasion (T3a) or invasion to the seminal vesicles (T3b), invasion to\n             adjacent structures (T4) but without lymphatic invasion (N0) nor metastasis (M0))\n\n          3. Prostatectomy or radiotherapy completed within 3 months prior to the study enrolment\n\n          4. High (T3a or Gleason score = 8-10 or PCA >20 ng/ml) and very high (T3b-T4) risk of\n             recurrence\n\n          5. Hystologically confirmed diagnosis of prostate adenocarcinoma\n\n        Exclusion Criteria:\n\n          1. Patients participating in clinical trials\n\n          2. Any medical condition which on the opinion of the investigator may interfere with the\n             patient's participation in the study, e.g. severe non-malignant concomitant disease\n             which can affect life expectancy\n\n          3. Evidence of metastatic disease on imaging studies"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Male patients with locally advanced prostate cancer with high and very high risk of\n        recurrence, who underwent surgery or radiotherapy within 3 months prior to enrolment, 18\n        years and older, consented to participate in this non-interventional study, being treated\n        for prostate cancer in the oncology institutions / departments in the Russian Federation."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155998", 
            "org_study_id": "NIS-ORU-XXX-2014/2"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "prostate adenocarcinoma, locally advanced prostate cancer with high and very high risk of recurrence, adjuvant endocrine treatment, prostate specific antigen", 
        "lastchanged_date": "June 3, 2014", 
        "number_of_groups": "1", 
        "official_title": "A Non-interventional Study of Postoperative or Post-Radiation trEatment Habits in Locally adVanced Prostate Cancer patiENTs (High Risk)- PREVENT", 
        "overall_contact": {
            "email": "Vera.Karaseva@astrazeneca.com", 
            "last_name": "Vera Karaseva", 
            "phone": "+7 495 799 56 99", 
            "phone_ext": "1520"
        }, 
        "overall_contact_backup": {
            "email": "Olga.Vedrova@astrazeneca.com", 
            "last_name": "Olga Vedrova", 
            "phone": "+7 495 799 56 99"
        }, 
        "overall_official": [
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Karin Otter", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Moscow Research Institute of Oncology named after PA Herzen", 
                "last_name": "Boris Alexeev", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Russian Cancer Research Center named after NN Blokhin", 
                "last_name": "Vsevolod Matveev", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Russia: Independent Interdisciplinary Committee of ethical review of clinical trials", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of adjuvant endocrine therapy: drugs used for androgen deprivation therapy, regimen, dose, duration", 
            "measure": "Evaluation of adjuvant endocrine therapy: drugs used for androgen deprivation therapy, regimen, dose, duration", 
            "safety_issue": "No", 
            "time_frame": "up to 15 months after LSI"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155998"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Data collection of patients characteristics (age, race, co-morbidities, family history of prostate cancer)", 
                "measure": "Data collection of patients characteristics (age, race, co-morbidities, family history of prostate cancer)", 
                "safety_issue": "No", 
                "time_frame": "up to 15 months after LSI"
            }, 
            {
                "description": "Data collection of disease information ( disease stage - TNM, hystology, Gleason score, PSA level, prior prostate cancer surgery/radiotherapy -types, imaging techniques, neoadjuvant and adjuvant therapy(medications by groups, orchidectomy)", 
                "measure": "Data collection of disease information ( disease stage - TNM, hystology, Gleason score, PSA level, prior prostate cancer surgery/radiotherapy -types, imaging techniques, neoadjuvant and adjuvant therapy(medications by groups, orchidectomy)", 
                "safety_issue": "No", 
                "time_frame": "up to 15 months after LSI"
            }, 
            {
                "description": "Proportion of patients with double increase in PSA level during 1 year follow-up", 
                "measure": "Proportion of patients with double increase in PSA level during 1 year follow-up", 
                "safety_issue": "No", 
                "time_frame": "up to 15 months after LSI"
            }, 
            {
                "description": "Proportion of progression-free patients after 1 year follow-up", 
                "measure": "Proportion of progression-free patients after 1 year follow-up", 
                "safety_issue": "No", 
                "time_frame": "up to 15 months after LSI"
            }, 
            {
                "description": "Proportion of patients with disease progression after 1 year follow-up", 
                "measure": "Proportion of patients with disease progression after 1 year follow-up", 
                "safety_issue": "No", 
                "time_frame": "up to 15 months after LSI"
            }, 
            {
                "description": "Proportion of patients having biochemical relapse after 1 year follow-up", 
                "measure": "Proportion of patients having biochemical relapse after 1 year follow-up", 
                "safety_issue": "No", 
                "time_frame": "up to 15 months after LSI"
            }, 
            {
                "description": "Proportion of patients having clinical relapse (local or metastatic) after 1 year follow-up", 
                "measure": "Proportion of patients having clinical relapse (local or metastatic) after 1 year follow-up", 
                "safety_issue": "No", 
                "time_frame": "up to 15 months after LSI"
            }, 
            {
                "description": "Evaluation of deaths among BRCAm+ patient", 
                "measure": "Evaluation of deaths among BRCAm+ patient", 
                "safety_issue": "No", 
                "time_frame": "up to 15 months after LSI"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}